Virtual Patient Case Sharing Across Two Schools of Pharmacy.
Michael A Smith1, Laura A Siemianowski1, Neal Benedict2
1Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, Pennsylvania.
American Journal of Pharmaceutical Education
|January 17, 2017
Summary
Sharing virtual patient cases between pharmacy schools significantly improved student learning and satisfaction. This collaborative approach overcomes faculty resource barriers, making virtual patient programs more accessible and effective for education.
Area of Science:
- Pharmacy Education
- Medical Simulation
Background:
- Virtual patients (VPs) are valuable educational tools in pharmacy.
- Implementation can be hindered by faculty time and resource constraints.
Purpose of the Study:
- To assess the feasibility and impact of sharing virtual patient cases between two pharmacy schools.
- To evaluate the effect of case sharing on faculty workload and student learning outcomes.
Main Methods:
- Two pharmacy schools collaborated to develop and share interactive virtual patient cases using vpSim and DecisionSim.
- Faculty time for case development and modification was recorded.
- Faculty perceptions and student satisfaction were assessed via surveys.
- Student learning was measured using pre- and post-tests.
Main Results:
- Sharing cases reduced development time from 22 hours/case to 1.2 hours/case.
- Faculty and students reported high satisfaction with the case-sharing model.
- Virtual patient cases significantly improved student learning scores (3.2 to 3.6 on a 5-point scale).
Conclusions:
- Virtual patient case sharing is an effective strategy to overcome implementation barriers in pharmacy education.
- This collaborative model enhances faculty efficiency and demonstrably improves student learning and satisfaction.
More Related Videos
Related Concept Videos
01:26Pharmaceutical Poisoning: Potential Scenarios
48
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
48
01:27Nursing Clinical Information System
1.3K
Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
1.3K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
405
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
58
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
58
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
218
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
218
01:19Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K